Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from cancer and leukemia group B 89803

Jeffrey A. Meyerhardt, Donna Niedzwiecki, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Heidi Nelson, Renaud Whittom, Alexander Hantel, James Thomas, Charles S. Fuchs

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Purpose: Obesity is a risk factor for the development of colon cancer. However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied. Patients and Methods: We conducted a prospective, observational study of 1,053 patients who had stage III colon cancer and who were enrolled on a randomized trial of adjuvant chemotherapy. Patients reported on height and weight during and 6 months after adjuvant chemotherapy. Patients were observed for cancer recurrence or death. Results: In this cohort of patients with stage III cancer, 35% of patients were overweight (BMI, 25 to 29.9 kg/m2), and 34% were obese (BMI ≥ 30 kg/m2). Increased BMI was not significantly associated with a higher risk of colon cancer recurrence or death (P trend = .54). Compared with normal-weight patients (BMI, 21 to 24.9 kg/m2), the multivariate hazard ratio for disease-free survival was 1.00 (95% CI, 0.72 to 1.40) for patients with class I obesity (BMI, 30 to 34.9 kg/m2) and 1.24 (95% CI, 0.84 to 1.83) for those with class II to III obesity (BMI ≥ 35 kg/m 2) after analysis was adjusted for tumor-related prognostic factors, physical activity, tobacco history, performance status, age, and sex. Similarly, after analysis was controlled for BMI, weight change (either loss or gain) during the time period between ongoing adjuvant therapy and 6 months after completion of therapy did not significantly impact on cancer recurrence and/or mortality. Conclusion: Neither BMI nor weight change was significantly associated with an increased risk of cancer recurrence and death in patients with colon cancer.

Original languageEnglish (US)
Pages (from-to)4109-4115
Number of pages7
JournalJournal of Clinical Oncology
Volume26
Issue number25
DOIs
StatePublished - 2008

Fingerprint

Colonic Neoplasms
Leukemia
Body Mass Index
Weights and Measures
Recurrence
Survival
Neoplasms
Therapeutics
Obesity
Adjuvant Chemotherapy
Disease-Free Survival
Tobacco
Observational Studies
History
Prospective Studies
Exercise
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer : Findings from cancer and leukemia group B 89803. / Meyerhardt, Jeffrey A.; Niedzwiecki, Donna; Hollis, Donna; Saltz, Leonard B.; Mayer, Robert J.; Nelson, Heidi; Whittom, Renaud; Hantel, Alexander; Thomas, James; Fuchs, Charles S.

In: Journal of Clinical Oncology, Vol. 26, No. 25, 2008, p. 4109-4115.

Research output: Contribution to journalArticle

Meyerhardt, Jeffrey A. ; Niedzwiecki, Donna ; Hollis, Donna ; Saltz, Leonard B. ; Mayer, Robert J. ; Nelson, Heidi ; Whittom, Renaud ; Hantel, Alexander ; Thomas, James ; Fuchs, Charles S. / Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer : Findings from cancer and leukemia group B 89803. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 25. pp. 4109-4115.
@article{eef496c34f844f8eb28ab6b0d7d31636,
title = "Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from cancer and leukemia group B 89803",
abstract = "Purpose: Obesity is a risk factor for the development of colon cancer. However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied. Patients and Methods: We conducted a prospective, observational study of 1,053 patients who had stage III colon cancer and who were enrolled on a randomized trial of adjuvant chemotherapy. Patients reported on height and weight during and 6 months after adjuvant chemotherapy. Patients were observed for cancer recurrence or death. Results: In this cohort of patients with stage III cancer, 35{\%} of patients were overweight (BMI, 25 to 29.9 kg/m2), and 34{\%} were obese (BMI ≥ 30 kg/m2). Increased BMI was not significantly associated with a higher risk of colon cancer recurrence or death (P trend = .54). Compared with normal-weight patients (BMI, 21 to 24.9 kg/m2), the multivariate hazard ratio for disease-free survival was 1.00 (95{\%} CI, 0.72 to 1.40) for patients with class I obesity (BMI, 30 to 34.9 kg/m2) and 1.24 (95{\%} CI, 0.84 to 1.83) for those with class II to III obesity (BMI ≥ 35 kg/m 2) after analysis was adjusted for tumor-related prognostic factors, physical activity, tobacco history, performance status, age, and sex. Similarly, after analysis was controlled for BMI, weight change (either loss or gain) during the time period between ongoing adjuvant therapy and 6 months after completion of therapy did not significantly impact on cancer recurrence and/or mortality. Conclusion: Neither BMI nor weight change was significantly associated with an increased risk of cancer recurrence and death in patients with colon cancer.",
author = "Meyerhardt, {Jeffrey A.} and Donna Niedzwiecki and Donna Hollis and Saltz, {Leonard B.} and Mayer, {Robert J.} and Heidi Nelson and Renaud Whittom and Alexander Hantel and James Thomas and Fuchs, {Charles S.}",
year = "2008",
doi = "10.1200/JCO.2007.15.6687",
language = "English (US)",
volume = "26",
pages = "4109--4115",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer

T2 - Findings from cancer and leukemia group B 89803

AU - Meyerhardt, Jeffrey A.

AU - Niedzwiecki, Donna

AU - Hollis, Donna

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Nelson, Heidi

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Thomas, James

AU - Fuchs, Charles S.

PY - 2008

Y1 - 2008

N2 - Purpose: Obesity is a risk factor for the development of colon cancer. However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied. Patients and Methods: We conducted a prospective, observational study of 1,053 patients who had stage III colon cancer and who were enrolled on a randomized trial of adjuvant chemotherapy. Patients reported on height and weight during and 6 months after adjuvant chemotherapy. Patients were observed for cancer recurrence or death. Results: In this cohort of patients with stage III cancer, 35% of patients were overweight (BMI, 25 to 29.9 kg/m2), and 34% were obese (BMI ≥ 30 kg/m2). Increased BMI was not significantly associated with a higher risk of colon cancer recurrence or death (P trend = .54). Compared with normal-weight patients (BMI, 21 to 24.9 kg/m2), the multivariate hazard ratio for disease-free survival was 1.00 (95% CI, 0.72 to 1.40) for patients with class I obesity (BMI, 30 to 34.9 kg/m2) and 1.24 (95% CI, 0.84 to 1.83) for those with class II to III obesity (BMI ≥ 35 kg/m 2) after analysis was adjusted for tumor-related prognostic factors, physical activity, tobacco history, performance status, age, and sex. Similarly, after analysis was controlled for BMI, weight change (either loss or gain) during the time period between ongoing adjuvant therapy and 6 months after completion of therapy did not significantly impact on cancer recurrence and/or mortality. Conclusion: Neither BMI nor weight change was significantly associated with an increased risk of cancer recurrence and death in patients with colon cancer.

AB - Purpose: Obesity is a risk factor for the development of colon cancer. However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied. Patients and Methods: We conducted a prospective, observational study of 1,053 patients who had stage III colon cancer and who were enrolled on a randomized trial of adjuvant chemotherapy. Patients reported on height and weight during and 6 months after adjuvant chemotherapy. Patients were observed for cancer recurrence or death. Results: In this cohort of patients with stage III cancer, 35% of patients were overweight (BMI, 25 to 29.9 kg/m2), and 34% were obese (BMI ≥ 30 kg/m2). Increased BMI was not significantly associated with a higher risk of colon cancer recurrence or death (P trend = .54). Compared with normal-weight patients (BMI, 21 to 24.9 kg/m2), the multivariate hazard ratio for disease-free survival was 1.00 (95% CI, 0.72 to 1.40) for patients with class I obesity (BMI, 30 to 34.9 kg/m2) and 1.24 (95% CI, 0.84 to 1.83) for those with class II to III obesity (BMI ≥ 35 kg/m 2) after analysis was adjusted for tumor-related prognostic factors, physical activity, tobacco history, performance status, age, and sex. Similarly, after analysis was controlled for BMI, weight change (either loss or gain) during the time period between ongoing adjuvant therapy and 6 months after completion of therapy did not significantly impact on cancer recurrence and/or mortality. Conclusion: Neither BMI nor weight change was significantly associated with an increased risk of cancer recurrence and death in patients with colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=51649093534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649093534&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.15.6687

DO - 10.1200/JCO.2007.15.6687

M3 - Article

C2 - 18757324

AN - SCOPUS:51649093534

VL - 26

SP - 4109

EP - 4115

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -